Big Pharma's R&D Booster Shot
In the late 1990s, scores of U.S. multinationals were catching on to the cost-cutting benefits of sending work to Asia. Not Big Pharma. The industry was bulging with profits and confidence. Whatever money could be saved by shifting drug development work to India or China would have seemed inconsequential compared with the billions of dollars at stake in a potential new blockbuster.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Fewest Jobless Claims Since 1973 Show Firm U.S. Job Market
- Germans Are Going Wild for a Show Set During the Dawn of the Nazis
- GE's New CEO Slashes Profit Outlook, Sends Shares Tumbling
- The U.K.'s $86 Billion Pension Problem Is About to Solve Itself
- U.S. Senate Adopts Budget, Giving Momentum to Trump's Tax-Cut Plans